These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 24954676)

  • 1. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.
    Schapira AH; Olanow CW; Greenamyre JT; Bezard E
    Lancet; 2014 Aug; 384(9942):545-55. PubMed ID: 24954676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.
    Chaturvedi RK; Beal MF
    Mol Cell Neurosci; 2013 Jul; 55():101-14. PubMed ID: 23220289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mitochondria for neuroprotection in Parkinson's disease.
    Schapira AH
    Antioxid Redox Signal; 2012 May; 16(9):965-73. PubMed ID: 22229791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
    Outeiro TF; Giorgini F
    Biotechnol J; 2006 Mar; 1(3):258-69. PubMed ID: 16897706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
    Alexi T; Borlongan CV; Faull RL; Williams CE; Clark RG; Gluckman PD; Hughes PE
    Prog Neurobiol; 2000 Apr; 60(5):409-70. PubMed ID: 10697073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.
    Chen CM
    Chang Gung Med J; 2011; 34(2):135-52. PubMed ID: 21539755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
    Bodner RA; Outeiro TF; Altmann S; Maxwell MM; Cho SH; Hyman BT; McLean PJ; Young AB; Housman DE; Kazantsev AG
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4246-51. PubMed ID: 16537516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
    Aviles-Olmos I; Limousin P; Lees A; Foltynie T
    Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease.
    Corona JC; Duchen MR
    Free Radic Biol Med; 2016 Nov; 100():153-163. PubMed ID: 27352979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroprotective effect of baicalein in patients with Parkinson's disease].
    Yu X; He G; Du G
    Zhongguo Zhong Yao Za Zhi; 2012 Feb; 37(4):421-5. PubMed ID: 22667137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides.
    Singh K; Gupta JK; Kumar S; Soni U
    Curr Protein Pept Sci; 2024; 25(7):507-526. PubMed ID: 38561605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.
    Yang X; Zhang Y; Xu H; Luo X; Yu J; Liu J; Chang RC
    Curr Top Med Chem; 2016; 16(8):858-66. PubMed ID: 26311425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal.
    Romano A; Serviddio G; Calcagnini S; Villani R; Giudetti AM; Cassano T; Gaetani S
    Free Radic Biol Med; 2017 Oct; 111():281-293. PubMed ID: 28063940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.
    Williams A; Jahreiss L; Sarkar S; Saiki S; Menzies FM; Ravikumar B; Rubinsztein DC
    Curr Top Dev Biol; 2006; 76():89-101. PubMed ID: 17118264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Huntington's and Parkinson's Disease.
    O'Keeffe GC; Michell AW; Barker RA
    Ann N Y Acad Sci; 2009 Oct; 1180():97-110. PubMed ID: 19906264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease.
    Büeler H
    Apoptosis; 2010 Nov; 15(11):1336-53. PubMed ID: 20131004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.